Privium Fund Management B.V. Acquires New Shares in Neurocrine Biosciences, Inc. $NBIX

Privium Fund Management B.V. acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the third quarter, HoldingsChannel.com reports. The institutional investor acquired 26,200 shares of the company’s stock, valued at approximately $3,716,000. Neurocrine Biosciences accounts for 0.7% of Privium Fund Management B.V.’s investment portfolio, making the stock its 27th largest holding.

Other institutional investors have also added to or reduced their stakes in the company. NewEdge Advisors LLC grew its position in Neurocrine Biosciences by 0.5% in the first quarter. NewEdge Advisors LLC now owns 13,066 shares of the company’s stock valued at $1,721,000 after purchasing an additional 68 shares in the last quarter. Westpac Banking Corp boosted its stake in shares of Neurocrine Biosciences by 6.0% during the 1st quarter. Westpac Banking Corp now owns 1,615 shares of the company’s stock worth $213,000 after buying an additional 91 shares during the last quarter. Meiji Yasuda Life Insurance Co boosted its stake in shares of Neurocrine Biosciences by 1.8% during the 2nd quarter. Meiji Yasuda Life Insurance Co now owns 5,628 shares of the company’s stock worth $949,000 after buying an additional 100 shares during the last quarter. ProShare Advisors LLC grew its holdings in shares of Neurocrine Biosciences by 1.7% in the 3rd quarter. ProShare Advisors LLC now owns 7,388 shares of the company’s stock valued at $1,048,000 after acquiring an additional 124 shares in the last quarter. Finally, Brookstone Capital Management grew its holdings in shares of Neurocrine Biosciences by 2.7% in the 3rd quarter. Brookstone Capital Management now owns 4,809 shares of the company’s stock valued at $682,000 after acquiring an additional 128 shares in the last quarter. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Trading Up 3.0%

Shares of NBIX traded up $4.87 during midday trading on Friday, reaching $164.63. The stock had a trading volume of 1,507,459 shares, compared to its average volume of 1,232,670. The firm has a 50 day simple moving average of $147.22 and a 200-day simple moving average of $148.05. Neurocrine Biosciences, Inc. has a one year low of $122.14 and a one year high of $186.12. The firm has a market cap of $16.73 billion, a PE ratio of 24.43, a P/E/G ratio of 0.64 and a beta of 0.36.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Monday, November 2nd. The company reported $3.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $1.38. Neurocrine Biosciences had a net margin of 18.98% and a return on equity of 24.11%. The company had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.04 billion. During the same period in the prior year, the firm earned $2.04 EPS. Neurocrine Biosciences’s quarterly revenue was up 41.3% compared to the same quarter last year. As a group, research analysts forecast that Neurocrine Biosciences, Inc. will post 7.66 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on NBIX. TD Cowen lifted their target price on Neurocrine Biosciences from $200.00 to $220.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Canaccord Genuity Group increased their price target on Neurocrine Biosciences from $210.00 to $220.00 and gave the company a “buy” rating in a research report on Tuesday. BMO Capital Markets decreased their price target on Neurocrine Biosciences from $164.00 to $150.00 and set a “market perform” rating for the company in a research note on Monday, October 12th. Cantor Fitzgerald boosted their price target on Neurocrine Biosciences from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Finally, Zacks Research cut Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $202.32.

Insiders Place Their Bets

In other Neurocrine Biosciences news, insider David Boyer sold 826 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $157.45, for a total value of $130,053.70. Following the sale, the insider owned 8,722 shares in the company, valued at $1,373,278.90. This represents a 8.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Matt Abernethy sold 2,311 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $157.20, for a total value of $363,289.20. Following the completion of the sale, the chief financial officer directly owned 42,808 shares of the company’s stock, valued at approximately $6,729,417.60. The trade was a 5.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 18,137 shares of company stock valued at $2,829,332 over the last 90 days. 4.60% of the stock is currently owned by insiders.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.